A Phase I Single and Multiple Dose Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of HS-10522 in Healthy Chinese Participants and Chinese Participants With Mild Hypertension
A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Oral Doses of HS-10522 Tablets in Healthy Chinese Participants and Chinese Participants With Mild Hypertension
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Phase 1
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
-
For all participants:
- Able to understand the procedures and methods of the study, willing to strictly adhere to the clinical trial protocol to complete the study, and voluntarily sign the Informed Consent Form (ICF).
- Male or female participants aged 18 to 55 years (inclusive) at the time of signing ICF.
- At screening, body weight ≥ 50 kg for males and ≥ 45 kg for females, with a body mass index (BMI) between 19.0 and 28.0 kg/m² (inclusive).
Exclusion Criteria:
- Abnormal vital signs, physical examination findings, or laboratory test results at screening that are deemed clinically significant by the investigator.
- Presence of orthostatic hypotension or orthostatic tachycardia at screening.
- Clinically significant abnormal findings on the 12-lead ECG at screening, as judged by the investigator.
- Use of any medication within 2 weeks or 5 half-lives (whichever is longer) prior to screening, or anticipation of needing such medication during the trial.
- Known secondary causes of hypertension, or diseases that may affect adrenal function (e.g., renal artery stenosis, poorly controlled or untreated hyperthyroidism, poorly controlled or untreated hypothyroidism, hyperparathyroidism, pheochromocytoma, Cushing's syndrome).
- Participation in any other clinical trial of a drug or medical device within 12 weeks prior to screening, with receipt of at least one dose (including placebo), or currently within 5 half-lives of the last dose of the investigational product (whichever is longer).
- Participants who, in the opinion of the investigator, are likely to be non-compliant or are unsuitable for participation in this trial for any other reason.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: HS-10522
|
HS-10522 tablet, oral, single ascending dose and multiple ascending dose, once daily
|
|
Placebo Comparator: HS-10522 Placebo
|
HS-10522 placebo , oral, single ascending dose and multiple ascending dose, once daily
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Incidence of adverse events following single and multiple doses of HS-10522 in healthy participants and participants with mild hypertension
Time Frame: SAD: 0 to 7 days after dosing; MAD: 0 to 14 days after dosing
|
Safety and tolerability will be assessed by comparison of number of adverse events between groups
|
SAD: 0 to 7 days after dosing; MAD: 0 to 14 days after dosing
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Maximum plasma concentration (Cmax)
Time Frame: -0.5 to 120 hour after dosing
|
-0.5 to 120 hour after dosing
|
|
|
time to maximum plasma concentration (Tmax)
Time Frame: -0.5 to 120 hour after dosing
|
-0.5 to 120 hour after dosing
|
|
|
area under the curve (AUC)
Time Frame: -0.5 to 120 hour after dosing
|
-0.5 to 120 hour after dosing
|
|
|
half-life
Time Frame: -0.5 to 120 hour after dosing
|
-0.5 to 120 hour after dosing
|
|
|
apparent volume of distribution (Vz/F)
Time Frame: -0.5 to 120 hour after dosing
|
-0.5 to 120 hour after dosing
|
|
|
apparent oral clearance (CL/F) of HS-10522
Time Frame: -0.5 to 120 hour after dosing
|
-0.5 to 120 hour after dosing
|
|
|
Plasma aldosterone following single and multiple oral doses of HS-10522
Time Frame: 0 to 96 hour after dosing
|
0 to 96 hour after dosing
|
|
|
Cortisol following single and multiple oral doses of HS-10522
Time Frame: 0 to 96 hour after dosing
|
0 to 96 hour after dosing
|
|
|
Metabolites levels following single and multiple oral doses of HS-10522
Time Frame: 0 to 96 hour after dosing
|
0 to 96 hour after dosing
|
|
|
(Exploratory) Mean seated systolic and diastolic blood pressure change compared with baseline
Time Frame: 14 days after dosing
|
Blood pressure measurement will be performed only in MAD part
|
14 days after dosing
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Estimated)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- HS-10522-101
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.